CYTO (Altamira Therapeutics) Gross Margin

CYTO (Altamira Therapeutics) - company brandmark

Risks of dependence on legacy products necessitate a transition to an RNA-delivery IT platform, as confirmed by the median gross margin, where this metric equals 0.00. Altamira Therapeutics (CYTO) ensures stability through the creation of inhalation agents for lung and allergy therapy. Business resilience is further bolstered by adherence to bioethics, safe waste disposal, and the integration of ESG principles into the development of nasal sprays.

Altamira Therapeutics (CYTO): Gross Margin from 07/04/2022 to 01/04/2025

Financial and market metric breakdowns for Altamira Therapeutics Ltd. (CYTO)

Summary company analysis:Altamira Therapeutics Ltd. (CYTO)
Manufactured products of altamiratherapeutics.com

Gross margin reflects the portion of revenue remaining after deducting direct production costs. This ratio measures the efficiency of cost-of-goods-sold management, allowing investors to assess the business's ability to generate profit before accounting for operating expenses. By analyzing the marginal income from gross profit, one can see how the nanoparticle intellectual property of Altamira Therapeutics (CYTO) creates high added value, protecting profitability from competition in the high-cost RNA therapy sector.

Key competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Gross Return on Sales|lexariabioscience.com - Return on Gross Profit|Gross Margin Pulmatrix Inc PULM|Pheton Holdings - Gross Margin|Gross Profitability Margin APM|Lyra Therapeutics, Inc. (LYRA) - Gross Profitability|Gross Profit Margin Impact BioMedical, Inc. (IBO)|Gross Profitability TNF Pharma|YCBD: Gross Profit Rate|Gross Margin PRFX|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin